Abstract
Background The broadly neutralizing antibody 2G12 is uniquely capable of recognizing the self-carbohydrate shield on the HIV-1 envelope glycoprotein gp120 and escaping immune tolerance. The preferred substrate of 2G12 is the Man4(D1)-arm of high-mannose glycans clustered on the gp120 outer surface. Remarkably, 2G12 has been shown to exhibit higher affinity for the non-self monosaccharide D-fructose than for D-mannose. D-fructose, in its pyranose form, resembles D-mannose, but with different substitutions at the anomeric and C-5 positions. These observations suggested other 'non-self' modifications to D-mannose may also enhance 2G12 binding. We consequently found that D-mannose with a C-6 methyl substitution binds 2G12 more strongly than both D-mannose and D-fructose. Moreover, introduction of this non-self modification to the terminus of the D1-arm creates the most potent monovalent 2G12 ligand known. We uncover here the molecular basis of this enhanced antigenicity, and the higher affinity of 2G12 for D-fructose over D-mannose, through high resolution crystallographic analyses.
Highlights
Open AccessMolecular mechanisms for enhancing the antigenicity of the carbohydrate epitope of the broadly neutralizing anti-HIV-1 antibody 2G12
The broadly neutralizing antibody 2G12 is uniquely capable of recognizing the self-carbohydrate shield on the HIV-1 envelope glycoprotein gp120 and escaping immune tolerance
We found that D-mannose with a C-6 methyl substitution binds 2G12 more strongly than both D-mannose and D-fructose
Summary
Molecular mechanisms for enhancing the antigenicity of the carbohydrate epitope of the broadly neutralizing anti-HIV-1 antibody 2G12. Z Fulton*1, KJ Doores, CN Scanlan, MR Wormald, RA Dwek, IA Wilson and BG Davis. Address: 1Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA and 2University of Oxford, Oxford, UK * Corresponding author from AIDS Vaccine 2009 Paris, France. Published: 22 October 2009 Retrovirology 2009, 6(Suppl 3):P323 doi:10.1186/1742-4690-6-S3-P323. AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.